Chengdu Pilot discloses performance report: core business is recovering for the better

The Innovation Capability Matrix continues to unleash growth potential in Chengdu, April 25, 2024/PRNewswire/ -- On the evening of April 24, Chengdu Pilot Pharmaceutical Development Co., Ltd. (stock code: 688222.SH, hereinafter referred to as “Chengdu Pilot” or “Company”) announced the 2023 Annual Report and the 2024 First Quarter Report (hereinafter referred to as “Annual Report” and “Quarterly Report”, respectively). Since 2023, with the gradual resumption of cross-border exchanges at home and abroad, the company has further optimized its international and domestic market strategies and continued to expand its business scope and partners.

PR NewswireApr 25 01:54 ET

Chengdu Pioneer (688222.SH) announced its 2023 annual results, with net profit of 40.72 million yuan, an increase of 61.16% over the previous year

Chengdu Pioneer (688222.SH) disclosed its 2023 annual report, and the company achieved revenue of 3 in 2023...

Zhitong FinanceApr 24 07:28 ET

Are HitGen Inc.'s (SHSE:688222) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

It is hard to get excited after looking at HitGen's (SHSE:688222) recent performance, when its stock has declined 22% over the past three months. It seems that the market might have completely ignor

Simply Wall StApr 16 21:59 ET

Chengdu Pilot (688222.SH): AI models are all self-developed or jointly developed with partners, and there is no external procurement

Gelonghui, March 21丨Chengdu Xiandao (688222.SH) said on the interactive platform that at present, Chengdu Pilot's AI technology mainly focuses on molecular discovery and optimization, training and iteration of experimental data based on large model+DEL screening test data, aimed at expanding the space of compounds with multiple target types, generating new molecules, improving compound properties, and increasing compound accessibility. The AI models pioneered in Chengdu were all developed in-house or jointly with partners, and there was no external procurement. As far as traditional Internet companies are concerned, the characteristics of Chengdu Pioneer in AI pharmaceuticals are: 1) Pilot's AI model has a larger number of actual experiments

Gelonghui FinanceMar 21 05:30 ET

Chengdu Pilot (688222.SH): It has nothing to do with the scope of restrictions in the draft Biosafety Act

Gelonghui, March 21丨Chengdu Xianjiao (688222.SH) said on an interactive platform that the company has also recently been concerned about statements and industry-related events in the US House of Representatives draft “Biosafety Act” involving restrictions on the use of genetic substances such as human genes by Chinese biotechnology companies. We would also like to explain: Since its establishment in 2012, Chengdu Xiantao has been focusing on the discovery and optimization of small molecules and new nucleic acid drugs, relying on DNA-coding compound library technology (including DEL library design, synthesis and expanded application), drug design based on molecular fragments and three-dimensional structural information Technology (FBDD/SB

Gelonghui FinanceMar 21 05:29 ET

Chengdu Pilot (688222.SH): Exploring various AI drug prediction, molecular generation, and optimization models

GLONGHUI, March 21丨Chengdu Xiandao (688222.SH) said on an interactive platform that in 2021, the company and Cambridge Molecular (Cambridge Small Molecule) announced the establishment of an exclusive alliance to efficiently provide potentially active, more readily available compounds for drug targets and accelerate compounds on Chengdu's leading DNA-coding Compound Library (DEL) technology platform, in combination with Cambridge Molecular's highly optimized deep machine learning system for DEL Verification of activity and widening of compound emptiness

Gelonghui FinanceMar 21 05:22 ET